Hanover, Germany

Heinrich-Wilhelm Ohlendorf


Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Garsbsen, DE (1987)
  • Garbsen, DE (1989)
  • Hanover, DE (1981 - 1990)

Company Filing History:


Years Active: 1981-1990

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Heinrich-Wilhelm Ohlendorf: Innovator in Pharmacological Compounds

Introduction

Heinrich-Wilhelm Ohlendorf is a notable inventor based in Hanover, Germany. He has made significant contributions to the field of pharmacology, particularly through his innovative work on 1-phenyl-2-aminocarbonylindole compounds. With a total of 8 patents to his name, Ohlendorf's inventions have the potential to impact medical treatments significantly.

Latest Patents

Ohlendorf's latest patents focus on novel 1-phenyl-2-aminocarbonylindole compounds. These compounds are characterized by a general formula that includes various substituents, which can be hydrogen atoms, lower alkyl groups, or halogen atoms. The pharmacological properties of these compounds, especially their antiarrhythmic effects, make them valuable in pharmaceutical applications. Additionally, the patents describe methods for preparing these compounds and their intermediates, as well as pharmaceutical compositions that incorporate them.

Career Highlights

Heinrich-Wilhelm Ohlendorf is associated with Kali-Chemie Pharma GmbH, where he has been instrumental in advancing research and development in pharmacological compounds. His work has not only contributed to the scientific community but has also paved the way for potential therapeutic applications in medicine.

Collaborations

Ohlendorf has collaborated with notable colleagues such as Wilhelm Kaupmann and Klaus-Ullrich Wolf. These partnerships have fostered a collaborative environment that enhances innovation and research in their field.

Conclusion

Heinrich-Wilhelm Ohlendorf's contributions to pharmacology through his innovative patents highlight his role as a significant inventor in the industry. His work continues to influence the development of new therapeutic compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…